Navigating the Evolving Role of B-Cell Therapies in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder

This MEDcast examines the role of B cells in the pathogenesis of myasthenia gravis and neuromyelitis optica spectrum disorder and how B-cell-targeted therapies are influencing clinical practice. Faculty discuss the evolution from traditional immunosuppressive approaches toward targeted biologic strategies, including considerations for treatment sequencing, steroid reduction, and earlier intervention. The discussion also highlights practical barriers to earlier use, including payer access, infusion logistics, and patient-specific considerations. Looking ahead, the faculty explore how emerging B-cell-directed approaches and growing clinical experience may further shape long-term treatment strategies in MG and NMOSD.